Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R T Swords
Expanded Safety Analysis of Pevonedistat, a First-In-Class NEDD8-activating Enzyme Inhibitor, in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Blood Cancer Journal
Oncology
Hematology
Related publications
Pevonedistat, a Nedd8-Activating Enzyme Inhibitor, Sensitizes Neoplastic B-Cells to Death Receptor-Mediated Apoptosis
Oncotarget
Oncology
CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Frontiers in Oncology
Cancer Research
Oncology
FLAMSA-RIC for Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine
Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Acute Myeloid Leukemia With Expanded Erythropoiesis
Haematologica
Hematology
Evaluation of Azacitidine in Patients With Transplant‑ineligible Myelodysplastic Syndromes and Acute Myeloid Leukemia With Myelodysplasia‑related Changes in a Japanese Clinical Setting
Oncology Letters
Cancer Research
Oncology
Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Leukemia Research
Cancer Research
Oncology
Hematology
The NEDD8-activating Enzyme Inhibitor MLN4924 Induces DNA Damage in Ph+ Leukemia and Sensitizes for ABL Kinase Inhibitors
Cell Cycle
Medicine
Developmental Biology
Cell Biology
Molecular Biology
